Commercial and development-stage biotechnology companies are expected to face minimal to no impact from the recent US executive order aimed at lowering drug prices, according to a Wednesday note by Euroz Hartleys.

Botanix Pharmaceuticals' (ASX:BOT) acne drug Sofdra is approved and sold solely in the United States, removing any reference price from foreign markets, Euroz said.

Specific measures in the executive order, including foreign importation, antitrust enforcement, pharmaceutical exports, or concerns around unsafe approvals, are not expected to affect BOT's business or products, Euroz added.

For pre-commercial firms like Dimerix (ASX:DXB), Euroz noted that it has based its revenue and valuation forecasts on modest, cautious pricing assumptions, which do not depend on the company being able to charge higher prices in the US compared to other countries.

Drug development companies, such as Argenica Therapeutics (ASX:AGN), Cynata Therapeutics (ASX:CYP), and Syntara (ASX:SNT), Euroz observed, are all still in the pre-commercial stage and are yet to have established product prices in the US or international markets.

Euroz believes that these companies have greater flexibility to adjust their pricing strategies in the future, should new policies, like the US drug pricing order, be implemented.

Euro Hartleys has assigned a buy rating on Botanix Pharmaceuticals with a price target of AU$0.80.

It also has a speculative buy rating on Argenica Therapeutics, Cynata Therapeutics, Dimerix, and Syntara with a price target of AU$1.40, AU$0.90, AU$1.68, and AU$0.30, respectively.